Post-transplant therapy in adult acute lymphoblastic leukemia patients
- Conditions
- Neoplasms
- Registration Number
- KCT0008883
- Lead Sponsor
- Kyungpook National University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 33
1) Patients who consented to the study
2) Age > 19, <70
3) Patients who diagnosed Philadelphila chromosome negative acute lymphoblastic leukemia and received standard chemotherapy
4) Complete remission status after allogeneic stem cell transplantation
5) Bone marrow blast < 5% after allogeneic stem cell transplantation & Patients who can receive decitabine (ANC > 1,000/uL & PLT > 50,000/uL)
6) Patients less than 100 days after allogeneic stem cell transplantation
7) Eastern Cooperative Oncology Group (ECOG) performance status 0-2
8) Patients with appropriate liver, kidney, heart function
9) A person who understands the contents of the clinical trial, is cooperative with the trial progress, and is judged to be able to participate until the end of the study
1) Pregnant or lactating women, or women who may become pregnant without adequate contraception
2) Previous history of hypomethylation treatment
3) Patients who have developed other malignant tumors within the past 5 years, excluding basal cell carcinoma of the skin, cervical carcinoma in situ, and papillary thyroid cancer that have been completely treated with the intention of cure
4) Other serious illnesses or medical conditions
5) Patients 100 days after allogeneic hematopoietic stem cell transplantation
6) Men who want to become pregnant or donate sperm during a clinical trial
7) Co-administration of other experimental drugs in clinical trials
8) Any other person deemed unsuitable by the researcher.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relapse rate
- Secondary Outcome Measures
Name Time Method Overall survival